DSM-Firmenich AG

DSFIR: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
?V?LOCK|!sLOCK|lw&H^$

DSM-Firmenich Earnings: Solid Organic Sales Growth; Guidance Increased After One-Off Vitamins Boon

DSM-Firmenich reported solid third-quarter earnings and upgraded the 2024 adjusted EBITDA guidance by 5% to EUR 2.1 billion, citing a one-off tailwind in the vitamins market.

Sponsor Center